← Back to Search

Device

Enhanced tDCS for Alzheimer's Disease

N/A
Recruiting
Research Sponsored by Baycrest
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months

Summary

This trial is testing whether a more intense electrical current can help people with Alzheimer's disease more than the standard current.

Who is the study for?
This trial is for individuals with mild to moderate Alzheimer's Disease, who score between 18 and 25 on the MoCA test, indicating their cognitive abilities. They must also have a certain score on the Cambridge Naming Task. People with significant heart disease, alcohol or drug abuse history, stroke or traumatic brain injury (TBI), or those with shunts or metal in their body cannot participate.
What is being tested?
The study is testing whether a stronger intensity of transcranial direct current stimulation (tDCS) at 4mA combined with naming training can improve language skills better than the conventional level of 2mA in people living with Alzheimer's Disease.
What are the potential side effects?
While tDCS is generally considered safe, potential side effects may include mild tingling, itching or burning sensation on the scalp where electrodes are placed; headache; fatigue; and nausea.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Naming Training

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 4mA StimulationExperimental Treatment1 Intervention
Group II: 2mA StimulationActive Control1 Intervention
Group III: SHAMPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Alzheimer's SocietyOTHER
9 Previous Clinical Trials
6,235 Total Patients Enrolled
BaycrestLead Sponsor
44 Previous Clinical Trials
6,423 Total Patients Enrolled

Media Library

transcranial direct current stimulation (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05509387 — N/A
Alzheimer's Disease Research Study Groups: 4mA Stimulation, 2mA Stimulation, SHAM
Alzheimer's Disease Clinical Trial 2023: transcranial direct current stimulation Highlights & Side Effects. Trial Name: NCT05509387 — N/A
transcranial direct current stimulation (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05509387 — N/A
~13 spots leftby Dec 2025